Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec:3:100017.
doi: 10.1016/j.bionps.2020.100017. Epub 2020 May 28.

Neurocognitive and neurophysiological endophenotypes in schizophrenia: An overview

Affiliations

Neurocognitive and neurophysiological endophenotypes in schizophrenia: An overview

Francesco Luciano Donati et al. Biomark Neuropsychiatry. 2020 Dec.

Abstract

Schizophrenia (SCZ) is a severe psychotic disorder that affects up to 1% of the US population and it is associated with progressive impairment in social functioning and cognition. Nonetheless, despite its high burden, the pathophysiology of SCZ, including the genetic and biological mechanisms underlying the development and manifestation of the disorder, remains largely elusive. Endophenotypes are subtypes of biological markers that are more closely related to the genetic vulnerability for a disorder (e.g., SCZ). Recently, research on endophenotypes has identified several parameters that may prove useful in shedding light over the underlying neurobiology of SCZ. In this article, we provide an overview of the most established SCZ endophenotypes in the domains of neurocognition (attention deficits, working and verbal declarative memory dysfunctions) and neurophysiology (pre-pulse inhibition, anti-saccade impairment, event-related potential deficits) along with some novel, sleep-based measures (reduced sleep spindles and sleep slow waves). We also discuss recent conceptual advances in the field that may lead to novel, personalized treatment interventions for patients affected by this devastating mental illness.

Keywords: Endophenotypes; Psychosis; Schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Desai PR, Lawson KA, Barner JC, Rascati KL, Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients, J. Managed Care Pharmacy JMCP 19 (6) (2013) 468–477, doi:10.18553/jmcp.2013.19.6.468. - DOI - PMC - PubMed
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V, Abu-Raddad LJ, Ackerman IN, Adamu AA, Adetokunboh O, Afarideh M, Afshin A, Agarwal SK, Aggarwal R, et al., Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet (London, England) 390 (10100) (2017) 1211–1259, doi:10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
    1. Tandon R, Nasrallah HA, Keshavan MS, Schizophrenia, “just the facts” 4. Clinical features and conceptualization, Schizophr. Res 110 (1–3) (2009) 1–23, doi:10.1016/j.schres.2009.03.005. - DOI - PubMed
    1. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis, Lancet 382 (9896) (2013) 951–962, doi:10.1016/S0140-6736(13)60733-3. - DOI - PubMed
    1. Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH, Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review, BMC Psychiatry 17 (1) (2017)12,doi:10.1186/s12888-016-1177-y. - DOI - PMC - PubMed